FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas

Media Relations ContactNicolas KressmannTel.: +1 [email protected]

Investor Relations ContactGeorge GrofikTel.: +33 (0)1 53 77 45 [email protected]